Compound Specifications CAS 49557-75-7 MW 340.38 Da Purity 99% (HPLC) Documentation & Lab Use Form: Lyophilized research material Documentation: Review the product label, batch records, and applicable laboratory SOPs before accessioning
Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, et al
approvals: T2D (Mounjaro, 2022), obesity (Zepbound, 2023), and obstructive sleep apnea with obesity (Zepbound, 2024) Ongoing Innovations in GLP-1s Landscape The obesity pipeline from phase 1 to market now includes 173 drugs, with GLP-1 and combination therapies accounting for majority of trials
Some may not have significant symptoms due to their deficiency, while others may experience tiredness, difficulty exerting themselves, numbness in the extremities, even balance and memory problems
Added to the formulation to buffer the acidity of the stomach
The vial should be stored in its original container or packaging as supplied, and kept away from direct sunlight or strong artificial light sources